FACTORS ASOCIATED WITH OSTEOPOROSIS AND BMD LOSS IN A COHORT OF WOMEN WITH BREAST CANCER TREATED WITH AROMATASE INHIBITORS

被引：0
|
作者：
Loarce-Martos, J. [1 ]
Sifuentes-Giraldo, W. A. [1 ]
Maldonado-Romero, L. V. [1 ]
Ahijon-Lana, M. [1 ]
Velazquez-Arce, C. [1 ]
Martinez-Janez, N. [1 ]
Vazquez-Diaz, M. [1 ]
机构：
[1] Hosp Univ Ramon Y Cajal, Madrid, Spain
来源：
OSTEOPOROSIS INTERNATIONAL | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P895
引用
收藏
页码：S445 / S445
页数：1
相关论文
共 50 条
  • [21] Attenuated peripheral endothelial function among women treated with aromatase inhibitors for breast cancer
    Maor, Ronny
    Sara, Jaskanwal D. S.
    Wanous, Amanda A.
    Maor, Elad
    Pruthi, Sandhya
    Lerman, Amir
    Sandhu, Nicole P.
    [J]. CORONARY ARTERY DISEASE, 2018, 29 (08) : 687 - 693
  • [22] Quality of Life of Women With Breast Cancer Treated in Adjuvant Setting With Tamoxifen or Aromatase Inhibitors
    Volovat, S.
    Apostol, D.
    Volovat, C.
    Carausu, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S379 - S379
  • [23] Aromatase inhibitors and bone health in women with breast cancer
    Chien, Amy Jo
    Goss, Paul E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (33) : 5305 - 5312
  • [24] Sulindac, a Nonselective NSAID, Reduces Breast Density in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors
    Thompson, Patricia A.
    Huang, Chuan
    Yang, Jie
    Wertheim, Betsy C.
    Roe, Denise
    Zhang, Xiaoyue
    Ding, Jie
    Chalasani, Pavani
    Preece, Christina
    Martinez, Jessica
    Chow, H-H Sherry
    Stopeck, Alison T.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5660 - 5668
  • [25] PERSISTENCE IN PATIENTS WITH BREAST CANCER TREATED WITH TAMOXIFEN OR AROMATASE INHIBITORS: RESULTS OF A RETROSPECTIVE COHORT STUDY
    Kostev, K.
    Haas, G.
    Hadji, P.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A428 - A428
  • [26] Erratum to: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper
    R. Rizzoli
    J. J. Body
    A. DeCensi
    J. Y. Reginster
    P. Piscitelli
    M. L. Brandi
    [J]. Osteoporosis International, 2012, 23 (11) : 2577 - 2577
  • [27] OSTEOPOROSIS SCREENING AND MANAGEMENT IN PATIENTS COMMENCING AROMATASE INHIBITORS FOR BREAST CANCER
    Rajak, Rizwan
    Bennett, Cheryl
    Williams, Ann
    Martin, James C.
    [J]. RHEUMATOLOGY, 2012, 51 : 102 - 102
  • [28] Survey on the Knowledge of Osteoporosis in Breast Cancer Patients Undergoing Aromatase Inhibitors
    Jiang, Zifang
    [J]. CANCER NURSING, 2016, 39 : S24 - S25
  • [29] ASSESSMENT OF OSTEOPOROSIS RISK IN PATIENTS INTIATING AROMATASE INHIBITORS FOR BREAST CANCER
    Dolan, L.
    Vandenbosch, P.
    Kendall, J.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S302 - S303
  • [30] Aromatase, aromatase inhibitors, and breast cancer
    Chumsri, Saranya
    Howes, Timothy
    Bao, Ting
    Sabnis, Gauri
    Brodie, Angela
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2011, 125 (1-2): : 13 - 22
12345